Evidence map›Paper›PMID 40243423›Full record

ArticleInternational journal of molecular sciences2025

Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients.

Christian Domingo, Daniel-Ross Monserrate, Markus Ollert, Xavier Pomares, Carles Forné, Jorge Del Estal, María José Amengual

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christian DomingoDepartment of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.ORCID 0000-0001-8358-773X
Daniel-Ross MonserrateDepartment of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.ORCID 0009-0000-1913-6547
Markus OllertClinical Research Division of Molecular and Clinical Allergotoxicology, Department of Dermatology and Allergy, Technische Universität München, 80802 Münich, Germany.ORCID 0000-0002-8055-0103
Xavier PomaresDepartment of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.ORCID 0000-0002-2783-414X
Carles FornéHeorfy Consulting, 25007 Lleida, Spain.ORCID 0000-0002-8133-3274
Jorge Del EstalPharmacy Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.ORCID 0000-0001-7299-2211
María José AmengualLaboratory Department, Immunology Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.ORCID 0000-0002-5385-3061

Funding

Ministry of Health FIS PI11/02303.
6 · The paper itself

Abstract

To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV

Indexed as

Adrenal Cortex HormonesAnti-Asthmatic AgentsAsthmaImmunoglobulin EOmalizumabAdministration, OralAdultBiomarkersFemaleForced Expiratory VolumeHumansMaleMiddle AgedTreatment OutcomeAdrenal Cortex HormonesAnti-Asthmatic AgentsBiomarkersImmunoglobulin EOmalizumabbiomarkerblood IgEclinical responsefree IgEomalizumabpredictor capacitysevere asthma

Identifiers

PMID40243423
PMCPMC11989120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.